Division of Thoracic Surgery, Centre Hospitalier Vaudois (CHUV), Lausanne, Switzerland.
Ann Surg Oncol. 2013 Feb;20(2):572-9. doi: 10.1245/s10434-012-2726-3. Epub 2012 Oct 28.
BACKGROUND: Resection of lung metastases (LM) from colorectal cancer (CRC) is increasingly performed with a curative intent. It is currently not possible to identify those CRC patients who may benefit the most from this surgical strategy. The aim of this study was to perform a systematic review of risk factors for survival after lung metastasectomy for CRC. METHODS: We performed a meta-analysis of series published between 2000 and 2011, which focused on surgical management of LM from CRC and included more than 40 patients each. Pooled hazard ratios (HR) were calculated by using random effects model for parameters considered as potential prognostic factors. RESULTS: Twenty-five studies including a total of 2925 patients were considered in this analysis. Four parameters were associated with poor survival: (1) a short disease-free interval between primary tumor resection and development of LM (HR 1.59, 95 % confidence interval [CI] 1.27-1.98); (2) multiple LM (HR 2.04, 95 % CI 1.72-2.41); (3) positive hilar and/or mediastinal lymph nodes (HR 1.65, 95 % CI 1.35-2.02); and (4) elevated prethoracotomy carcinoembryonic antigen (HR 1.91, 95 % CI 1.57-2.32). By comparison, a history of resected liver metastases (HR 1.22, 95 % CI 0.91-1.64) did not achieve statistical significance. CONCLUSIONS: Clinical variables associated with prolonged survival after surgery for LM in CRC patients include prolonged disease-free interval between primary tumor and metastatic spread, normal prethoracotomy carcinoembryonic antigen, absence of thoracic node involvement, and a single pulmonary lesion.
背景:越来越多的结直肠癌(CRC)患者采用以治愈为目的的肺转移灶切除术(LM)。目前还无法确定哪些 CRC 患者最能从这种手术策略中获益。本研究旨在对 CRC 患者 LM 切除术后生存的危险因素进行系统回顾。
方法:我们对 2000 年至 2011 年期间发表的系列研究进行了荟萃分析,这些研究主要侧重于 CRC 患者 LM 的手术治疗,每个研究均包含超过 40 名患者。对于被认为是潜在预后因素的参数,使用随机效应模型计算合并危险比(HR)。
结果:共 25 项研究,总计 2925 例患者被纳入本分析。四项参数与预后不良相关:(1)原发肿瘤切除与 LM 发展之间无病间期较短(HR 1.59,95%置信区间 [CI] 1.27-1.98);(2)多发 LM(HR 2.04,95% CI 1.72-2.41);(3)阳性肺门和/或纵隔淋巴结(HR 1.65,95% CI 1.35-2.02);(4)术前癌胚抗原升高(HR 1.91,95% CI 1.57-2.32)。相比之下,肝转移切除术史(HR 1.22,95% CI 0.91-1.64)无统计学意义。
结论:与 CRC 患者 LM 切除术后生存延长相关的临床变量包括原发肿瘤和转移扩散之间无病间期延长、术前癌胚抗原正常、无胸部淋巴结受累以及单个肺部病变。
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2022-9-26
Interact Cardiovasc Thorac Surg. 2016-12
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2021-4-19
Gen Thorac Cardiovasc Surg. 2025-7-21
Cardiovasc Intervent Radiol. 2025-4-28
Clin Colon Rectal Surg. 2024-6-18
J Gastrointest Surg. 2025-3
World J Gastrointest Oncol. 2024-8-15